Clinical Trials for Ovarian Cancer

Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed stage III–IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who responded to 3–4 cycles of neoadjuvant carboplatin/paclitaxel and are candidates for interval cytoreductive surgery are randomized to perioperative cisplatin either IV the day before surgery or as intraoperative HIPEC at the end of surgery. Compares safety/tolerability and feasibility of these cisplatin delivery strategies in the perioperative setting.

ClinicalTrials.gov ID: NCT05415709

Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent low-grade serous ovarian cancer (measurable disease, ECOG 0–2; up to 5 prior lines; no prior regorafenib or multi-kinase TKIs; limited prior anti-angiogenic therapy) receive regorafenib (oral multikinase inhibitor of VEGFR/PDGFR/FGFR/RAF; ReDOS ramp-up, 3 weeks on/1 week off) plus intramuscular fulvestrant 500 mg (SERD). Aims to assess early objective response and survival/clinical benefit, with safety monitoring and exploratory genomic correlates.

ClinicalTrials.gov ID: NCT05113368

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent mismatch repair–deficient endometrial carcinoma (non-serous, non-carcinosarcoma) after 1–2 prior lines are randomized to nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus nivolumab alone, including patients with treated/stable brain metastases and select stable autoimmune disease; prior PD-1/PD-L1 allowed only if part of combination therapy with ≥12-month CR interval. Treatment continues until progression/toxicity/CR with nivolumab maintenance permitted after CR.

ClinicalTrials.gov ID: NCT05112601

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors and ECOG performance status 0–1 receive LNCB74 monotherapy in dose-escalation and expansion cohorts. LNCB74 is an investigational B7-H4–targeted antibody–drug conjugate carrying the microtubule-disrupting payload MMAE.

ClinicalTrials.gov ID: NCT06774963

A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with unresectable or metastatic carcinoma, ECOG performance status 0–1, and a lesion available for pretreatment biopsy. Patients receive escalating or expansion doses of BMS-986463, an investigational molecular-glue degrader of the cell-cycle regulator WEE1 kinase.

ClinicalTrials.gov ID: NCT06476808

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with metastatic, measurable solid tumors (including GI, GU, breast, ovarian, endocrine tumors, NSCLC, and multiple myeloma with plasmacytomas) who have progressed after standard therapies, and treats them with autologous T-cells genetically engineered to express T-cell receptors targeting patient-specific tumor neoantigens, following lymphodepletion, with or without the addition of pembrolizumab. The investigational TCR therapy directly targets mutated or viral antigens unique to each patient’s cancer in an effort to induce durable tumor regression.

ClinicalTrials.gov ID: NCT03412877

A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced/Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable, unresectable advanced or metastatic solid tumors and ECOG 0–1 receive oral NKT3964 monotherapy, an investigational PROTAC that degrades CDK2. Expansion cohorts focus on HR-positive/HER2-negative breast cancer after CDK4/6 inhibition, CCNE1-amplified platinum-resistant or refractory ovarian cancer, and CCNE1-amplified gastroesophageal adenocarcinoma.

ClinicalTrials.gov ID: NCT06586957

Phase Ib/IIa Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls anthracycline-naive adults with measurable, treatment-refractory soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical or ovarian cancer, or KRAS-mutant pancreatic cancer after at least two prior therapies. Patients receive escalating doses of SPEDOX-6, a doxorubicin formulation encapsulated in human serum albumin that may preferentially deliver drug to tumors with low FcRn expression; FcRn testing is not required.

ClinicalTrials.gov ID: NCT07064018

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with selected advanced solid tumors, measurable disease, and ECOG performance status 0–1 receive once-weekly intravenous MT-4561, an investigational drug designed to degrade BRD4. Dose escalation is followed by planned dose optimization and an assessment of MT-4561’s effect on oral midazolam pharmacokinetics.

ClinicalTrials.gov ID: NCT06943521

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated unresectable or metastatic KRAS G12D–mutated solid tumors are eligible for dose escalation; dose expansion is limited to pancreatic ductal adenocarcinoma after at least one prior systemic therapy. All receive IV ARV-806, an investigational PROTAC designed to degrade mutant KRAS G12D, weekly or every two weeks.

ClinicalTrials.gov ID: NCT07023731